Harrow, Inc.
HROW
Positions held
Your positionsHROW isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Harrow, Inc. operates in the specialty and generic drug manufacturing industry, which is poised for growth due to increasing healthcare demands and an aging population.
- Revenue increased by 60% compared to the prior quarter, reaching $71 million.
- Gross margin improved to 71.3%, up from 61.2% in the previous quarter.
- The company's financials show a negative profit margin of -13.5%, indicating ongoing challenges in profitability.
- The operating margin remains negative at -15.6%, reflecting operational inefficiencies.
- The overall score indicates a 'Strong Sell' with a score of -24.00, highlighting significant bearish trends.
Fundamentals
| Market cap | $1.14B | Enterprise value | $1.36B | Trailing P/E | — | Forward P/E | 11.01 |
| PEG | — | Price / book | 75.17 | Beta | 0.19 | Dividend yield | 0.00% |
| Revenue growth | 10.9% | Earnings growth | — | Gross margin | 73.3% | Operating margin | -15.6% |
| Profit margin | -13.5% | ROE | -116.1% | ROA | -0.5% | Debt / equity | 20.26 |
| Current ratio | 2.24 | Free cash flow | -$5.49M | Analyst recommendation | strong_buy | Mean target | $65.00 |
| 52w high | $54.85 | 52w low | $28.54 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $70.7M | $44.2M | $89.1M | $71.6M | $63.7M |
| Op margin | -15.6% | -50.0% | 17.5% | 20.6% | 17.9% |
| Net income | -$17.3M | -$27.6M | $6.6M | $1.0M | $5.0M |
| Gross margin | 71.3% | 61.2% | 79.3% | 75.3% | 74.5% |
| Gross profit | $50.4M | $27.0M | $70.6M | $53.9M | $47.5M |
| Operating income | -$11.0M | -$22.1M | $15.6M | $14.7M | $11.4M |
- Revenue +60% vs prior quarter ($71M vs $44M).
- Gross margin 71.3% (was 61.2% prior quarter).
- Operating margin expanded to -15.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $272M | $200M | $130M | $88.6M | — |
| Op margin | 11.2% | 4.5% | 0.6% | 2.2% | — |
| Net income | -$5.1M | -$17.5M | -$24.4M | -$14.1M | — |
| Gross margin | 75.1% | 75.3% | 69.6% | 71.3% | — |
| Gross profit | $204M | $150M | $90.6M | $63.2M | — |
| Operating income | $30.5M | $9.1M | $0.8M | $1.9M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Is Harrow (HROW) Undervalued On Growing Conference Buzz Around Its Ophthalmic Pipeline?
2026-10-05 · Harrow Completes Acquisition of Tyrvaya Nasal Spray From Viatris
2026-10-05 · Harrow Closes Acquisition of TYRVAYA®
2026-09-30 · Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
2026-09-09 · Leerink Partners Initiates Coverage on Harrow With Outperform Rating, $45 Price Target
2026-09-03 · This Fund Bought Moderna Before It Nearly Tripled. See Its 2 New Stock Picks
2026-08-20 · Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target
2026-08-20 · Harrow's IHEEZO Cuts Patient-Reported Discomfort 58% in Intravitreal-Injection Study
2026-08-20 · Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
2026-08-17 · Harrow (HROW) Q2 2026 Earnings Call Transcript
2026-08-13 · Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
2026-08-12 · Harrow (HROW) Adds New Eye Care Firepower With Product Launch And Acquisition
Price (daily)
Full chart · RSI · MACD · patterns